UTI in Pakistan: ciprofloxacin is a one-in-four bet

A woman comes in with three days of dysuria and frequency. You write ciprofloxacin, because that is what you were taught and what everyone writes.

In two published Pakistani series, E. coli susceptibility to fluoroquinolones was 24% and 28%. You have roughly a one-in-four chance of having treated her.

What the local numbers actually show

Two Pakistani studies, different regions and periods. I have deliberately not pooled them, because their disagreement is the point.

The Islamabad data is a retrospective analysis of 12,000 samples from tertiary centres, community-acquired uncomplicated UTI, comparing 2005–2010 with 2016–2021. The Dera Ismail Khan data is cross-sectional, 610 specimens, 260 positive, 88% of patients rural.

Notice the pattern. The agents that still work agree across both series. The agents that have failed disagree wildly — co-amoxiclav retained 47% susceptibility in Islamabad and none at all in D.I. Khan. That tells you something important: fosfomycin and nitrofurantoin are reasonably safe bets nationally, but everything else depends on where you are. Your own hospital antibiogram beats every number in that table.

One more figure that should change how you read a cephalosporin result: in the D.I. Khan series, 81.6% of Enterobacteriaceae were ESBL producers.

Why co-trimoxazole is not the answer either

Several international guidelines make co-trimoxazole first-line for uncomplicated cystitis — but conditionally, where local susceptibility exceeds roughly 80%. At 27%, Pakistan does not meet the condition the guideline itself sets. The recommendation has not been misapplied so much as applied without checking its precondition.

So: nitrofurantoin or fosfomycin

Nitrofurantoin 100 mg modified-release twice daily, or 50 mg four times daily, for 3–5 days in women. The most consistent performer across both Pakistani series.

Fosfomycin trometamol as a single 3 g oral dose. The highest susceptibility in both series, and single-dose adherence is a real advantage where follow-up is unreliable. Worth knowing the trade-off: in a head-to-head trial, clinical resolution at day 28 was 70% with nitrofurantoin and 58% with fosfomycin. But a good drug abandoned on day two beats a better one nobody finishes.

The trap that comes with them

Here is the thing that makes UTI in Pakistan genuinely dangerous rather than merely inconvenient.

The two oral agents that still work are exactly the two that cannot treat pyelonephritis.

Nitrofurantoin does not achieve adequate concentrations in blood or deep renal tissue. Fosfomycin is likewise not a pyelonephritis drug. If you classify a patient with loin pain and fever as cystitis and write nitrofurantoin, you have not chosen a suboptimal drug — you have chosen one that cannot work, and the susceptibility report will look perfectly reassuring while it fails.

So the classification step matters more here than it does in settings where a fluoroquinolone would have covered both.

• Uncomplicated cystitis — non-pregnant woman, normal tract, no fever, no loin pain. Nitrofurantoin or fosfomycin.
• Complicated UTI — male, pregnant, catheterised, structural abnormality, stones, recent instrumentation, immunosuppression, poorly controlled diabetes. Culture before the first dose, always.
• Pyelonephritis — fever, rigors, loin pain, vomiting. Something that reaches renal tissue, guided by your antibiogram. Not these two.

Nitrofurantoin and G6PD: softer than you were taught

This matters because G6PD deficiency is common in Pakistan and usually undiagnosed, and because the classic teaching would delete one of only two working agents.

A safety review identified 318 reported episodes of nitrofurantoin-associated haemolytic anaemia. Only 42 of them — 13% — had confirmed or highly probable G6PD deficiency. Across roughly 245 million documented exposures, that works out at about 1.3 cases per million. Early erythrocyte-survival studies suggest nitrofurantoin is less likely to cause oxidant haemolysis than primaquine.

The review's practical recommendation: a total daily dose of 200 mg for a short 3–5 day course may be given without G6PD screening, provided the patient is warned about the signs of haemolysis — dark urine especially — and told to stop and seek review.

Labelling genuinely differs. The EMA lists a contraindication; the FDA provides only pharmacogenomic information. If your formulary contraindicates it, follow your formulary. But do not discard the drug on the strength of the classic teaching alone.

The renal threshold nobody agrees on

Nitrofurantoin needs adequate filtration to reach therapeutic urinary concentrations. The threshold has moved repeatedly: the Beers criteria shifted from avoiding it below a creatinine clearance of 60 to below 30 in their 2015 update, while other guidance advises avoiding it below an eGFR of 45 and requires no dose adjustment between 45 and 59.

Below 30, there is broad agreement not to use it. Between 30 and 45, the sources genuinely differ — decide with your formulary and the alternatives you actually have, rather than assuming one number is settled.

The highest-yield thing to stop doing

Do not treat asymptomatic bacteriuria. A positive culture is not an infection. Treating it does not prevent symptomatic infection, does not improve outcomes, and drives exactly the resistance in that table. The only exceptions are pregnancy and before a urological procedure expected to breach the mucosa.

Cloudy or strong-smelling urine is not a reason to treat. Neither is a positive dipstick in someone with no urinary symptoms.

One connection worth noticing

In the D.I. Khan series, 68% of patients with a positive urine culture had a history of diabetes. Pakistan has the highest national prevalence of type 2 diabetes in the world. A UTI is a reasonable prompt to check an HbA1c in someone not already known to be diabetic — and poor control puts the patient in the complicated category.

Bottom line

Ciprofloxacin and co-trimoxazole are not empiric options for cystitis in Pakistan. Nitrofurantoin and fosfomycin are. Classify carefully, because those same two agents cannot treat the kidney. Send cultures in complicated infection and pyelonephritis so carbapenems can be de-escalated rather than continued by default. Don't treat asymptomatic bacteriuria. And push for a hospital antibiogram — every number in this article is a substitute for one you should have.

Our UTI pathway works through this in six steps, with the classification driving the empiric recommendation directly and every statement labelled with how far it diverges from international guidance. It sits alongside pathways for community-acquired pneumonia, type 2 diabetes and hypertension.

ReviseFCPS1 is built by doctors in Pakistan, for doctors in Pakistan. All our clinical tools and pathways are free. If you are preparing for FCPS Part 1, try it free for 7 days — 10,176 doctor-verified MCQs and 8,236 real exam recalls.